FDA requires expanded labeling about weight loss risk in patients younger than 6 years taking extended-release stimulants for ADHD

The U.S. Food and Drug Administration (FDA) is revising labeling on all extended-release stimulants indicated to treat attention-deficit/hyperactivity disorder (ADHD), stating that patients younger than 6 years of age taking these medications are at greater risk of weight loss and other side effects compared with older children taking the same medication at the same dosage.